Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
The company also raised Rs 270 crore investment from Temasek in 2019
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Subscribe To Our Newsletter & Stay Updated
